Longitudinal Neurocognitive Changes for Patients With Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review With Structured Narrative Synthesis.

Eur J HaematolJun 7, 2026 (epub)
Clinical ResearchHematologyOncology (Medical)NeurologyOpen access

Kah Hui Yap, Wei Hoong Loo, Gin Gin Gan

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated longitudinal neurocognitive changes in patients with hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT). Nine studies were included, revealing that while improvements may occur post-HSCT, allogeneic HSCT and myeloablative conditioning are significant risk factors for persistent cognitive decline. Notably, executive function and attention/processing speed were identified as core deficits.

Key findings

  • Nine studies met inclusion criteria from an initial 2012, indicating moderate overall study quality.
  • Allogeneic HSCT and myeloablative conditioning were identified as main risk factors for cognitive decline.
  • Executive function and attention/processing speed impairments were core deficits linked to neurocognitive changes.

Why it matters

Understanding neurocognitive changes in patients undergoing HSCT is crucial, as these changes can significantly impact quality of life. Regular assessments and cognitive rehabilitation strategies may improve patient outcomes.

Source

PubMed · PMID 42252119Free full text on PubMed Central

Published in Eur J Haematol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.